HealthMed Holdings Announces Blood Test to Identify Heart Attack Risk
HealthMed Holdings’ MAP Test (Myocardial Assessment Profile) aims to identify individuals who are at risk of a heart attack and may be missed by conventional tests.
The MAP Test measures compounds in the blood associated with vascular inflammation causing unstable cardiac lesions. Measurement of these compounds in a person's serum enables identification of patients at risk of a heart attack in the near term. The MAP Test allows physicians to more effectively manage and treat their patients to the new ACC/AHA Cardiac guidelines, aiding in the reduction and prevention of cardiac events. Used in conjunction with other clinical information, the MAP Test's easy to understand results yield better compliance and behavioral changes by patients.
It completed validation in February 2014.